You are here:

fentanyl citrate (Breakyl)

Advice

in the absence of a submission from the holder of the marketing authorisation

fentanyl citrate (Breakyl®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: fentanyl citrate (Breakyl)
SMC Drug ID: 947/13
Manufacturer: Meda Pharmaceuticals Ltd
Indication: Treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 January 2014

Back